At the end of the CPE activity the Pharmacists will be able to:

• Review the pathophysiology, laboratory values and complications of hyperlipidemia.
• Assess the risk for cardiovascular events.
• Explain current guideline recommendations for the non-pharmacologic and pharmacologic treatments based on the patient’s goals.
• Examine benefits and risks of current and emerging LDL-C lowering pharmacotherapies.
• Identify new drugs approved by the FDA for hypercholesterolemia and their role in current practice.
• Describe the role of pharmacists in dyslipidemia management.